We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Idazoxan: A Selective α2-Antagonist and Effective Sustained Antidepressant in Two Bipolar Depressed Patients

Ossama T. Osman, MD; Matthew V. Rudorfer, MD; William Z. Potter, MD, PhD
Arch Gen Psychiatry. 1989;46(10):958-959. doi:10.1001/archpsyc.1989.01810100100021.
Text Size: A A A
Published online


To the Editor.—  We report on the therapeutic and biochemical effects of short- and long-term administration of idazoxan, a selective α2-administration and a putative antidepressant, in three patients with the diagnosis of depression and a history of poor response to standard treatments. The down regulation of central β-receptors in response to increased synaptic norepinephrine (NE) levels has consistently been demonstrated after tricyclic antidepressant1 as well as other effective treatments for depression.2,3 In addition, α2-adrenergic receptors have been shown to down regulate in response to at least some antidepressants.4,5 Furthermore, blockade of α-receptors can accelerate the down regulation of β-receptors by tricyclic antidepressants in rats,6 probably by enhancing intrasynaptic NE through the blockade of prejunctional α2-receptors that normally mediate feedback inhibition of NE release.7 In human studies, however, the addition of yohimbine therapy to patients who had failed to respond


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.